Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid

Journal of Virology

Volumn 86, Issue 16, 2012, Pages 8472-8481

  Kortagere, Sandhya ^a   Madani, Navid ^b   Mankowski, Marie K ^c   Schön, Arne ^d   Zentner, Isaac ^a   Swaminathan, Gokul ^a   Princiotto, Amy ^b   Anthony, Kevin ^e   Oza, Apara ^a   Sierra, Luz Jeannette ^a   Passic, Shendra R ^a   Wang, Xiaozhao ^f   Jones, David M ^f   Stavale, Eric ^e   Krebs, Fred C ^a   Martín García, Julio ^a   Freire, Ernesto ^d   Ptak, Roger G ^c   Sodroski, Joseph ^c   Cocklin, Simon ^a   Smith, Amos B ^f   more..

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e USA IBT Bioservices   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4,5 DIPHENYL 1H IMIDAZOL 2 YL)BENZOIC ACID; 4,4' [DIBENZO[B,D]FURAN 2,8 DIYLBIS(5 PHENYL 1H IMIDAZOLE 4,2 DIYL)]DIBENZOIC ACID; ANTIVIRUS AGENT; CAPSID PROTEIN; CK 026; UNCLASSIFIED DRUG; XW 053;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION; SURFACE PLASMON RESONANCE; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CALORIMETRY; CAPSID PROTEINS; CELL LINE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PLASMON RESONANCE; VIRUS INTERNALIZATION; VIRUS REPLICATION; VIRUS UNCOATING;

EID: 84865063652     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05006-11     Document Type: Article

References (48)

1. Blair WS, et al. 2010. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 6:e1001220. doi:10.1371/ journal.ppat.1001220.
2. Reference deleted
3. Reference deleted
4. Buckheit RW, Jr., Swanstrom R. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retroviruses 7:295-302.
5. Butler SL, Hansen MS, Bushman FD. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634.
6. Curreli F, et al. 2011. Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid. Bioorg. Med. Chem. 19:77-90.
7. Reference deleted
8. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677.
9. Ganser-Pornillos BK, et al. 2011. Hexagonal assembly of a restricting TRIM5alpha protein. Proc. Natl. Acad. Sci. U. S. A. 108:534-539.
10. Ganser-Pornillos BK, von Schwedler UK, Stray KM, Aiken C, Sundquist WI. 2004. Assembly properties of the human immunodeficiency virus type 1 CA protein. J. Virol. 78:2545-2552.
11. Han Y, et al. 2010. Solid-state NMR studies of HIV-1 capsid protein assemblies. J. Am. Chem. Soc. 132:1976-1987.
12. Reference deleted
13. Hulme AE, Perez O, Hope TJ. 2011. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 108:9975-9980.
14. Jin Y, et al. 2010. SAR and molecular mechanism study of novel acylhydrazone compounds targeting HIV-1 CA. Bioorg. Med. Chem. 18:2135-2140.
15. Jones G, Willett P, Glen RC, Leach AR, Taylor R. 1997. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:727-748.
16. Kelly BN, et al. 2007. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373:355-366.
17. Kortagere S, Chekmarev D, Welsh WJ, Ekins S. 2009. Hybrid scoring and classification approaches to predict human pregnane x receptor activators. Pharm. Res. 26:1001-1011.
18. Kortagere S, Welsh WJ. 2006. Development and application of hybrid structure based method for efficient screening of ligands binding to Gprotein coupled receptors. J. Comput. Aided Mol. Des. 20:789-802.
19. Lanier ER, et al. 2010. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/ nucleotide-resistant HIV. Antimicrob. Agents Chemother. 54:2901-2909.
20. Lemke CT, et al. 2012. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J. Virol. 86:6643-6655.
21. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
22. Liszewski MK, Yu JJ, O'Doherty U. 2009. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 47:254-260.
23. Madani N, Hubicki AM, Perdigoto AL, Springer M, Sodroski J. 2007. Inhibition of human immunodeficiency virus envelope glycoproteinmediated single cell lysis by low-molecular-weight antagonists of viral entry. J. Virol. 81:532-538.
24. Madani N, et al. 2008. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689-1701.
25. Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK. 2009. Real-time PCR analysis of HIV-1 replication post-entry events. Methods Mol. Biol. 485:55-72.
26. Mobley DL, Dill KA. 2009. Binding of small-molecule ligands to proteins: "what you see" is not always "what you get." Structure 17:489-498.
27. Monroe EB, Kang S, Kyere SK, Li R, Prevelige PE, Jr. 2010. Hydrogen/ deuterium exchange analysis of HIV-1 capsid assembly and maturation. Structure 18:1483-1491.
28. Noviello CM, et al. 2011. Second-site compensatory mutations of HIV-1 capsid mutations. J. Virol. 85:4730-4738.
29. Ohtaka H, Freire E. 2005. Adaptive inhibitors of the HIV-1 protease. Prog. Biophys. Mol. Biol. 88:193-208.
30. Pertel T, et al. 2011. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472:361-365.
31. Pornillos O, Ganser-Pornillos BK, Banumathi S, Hua Y, Yeager M. 2010. Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. J. Mol. Biol. 401:985-995.
32. Pornillos O, et al. 2009. X-ray structures of the hexameric building block of the HIV capsid. Cell 137:1282-1292.
33. Pornillos O, Ganser-Pornillos BK, Yeager M. 2011. Atomic-level modelling of the HIV capsid. Nature 469:424-427.
34. Ptak RG, et al. 2008. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 52:1302-1317.
35. Rho HM, Poiesz B, Ruscetti FW, Gallo RC. 1981. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 112:355-360.
36. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. 2010. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85:542-549.
37. Shin R, Tzou YM, Wong HC, Krishna NR. 2011. (1)H, (15)N, and (13)C resonance assignments for a monomeric mutant of the HIV-1 capsid protein. Biomol. NMR Assign. [Epub ahead of print.] doi:10.1007/s12104-011-9340-3.
38. Si Z, et al. 2004. Small-molecule inhibitors of HIV-1 entry block receptorinduced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 101:5036-5041.
39. Stremlau M, et al. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
40. Stremlau M, et al. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103:5514-5519.
41. Studier FW. 2005. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 41:207-234.
42. Tang C, et al. 2003. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327:1013-1020.
43. Thali M, et al. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
44. Tian B, et al. 2009. Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein. Bioorg. Med. Chem. Lett. 19:2162-2167.
45. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI. 2003. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 77:5439-5450.
46. Yeager M. 2011. Design of in vitro symmetric complexes and analysis by hybrid methods reveal mechanisms of HIV capsid assembly. J. Mol. Biol. 410:534-552.
47. Zhang H, et al. 2008. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J. Mol. Biol. 378:565-580.
48. Zhang Y, Qian H, Love Z, Barklis E. 1998. Analysis of the assembly function of the human immunodeficiency virus type 1 Gag protein nucleocapsid domain. J. Virol. 72:1782-1789.